Hatem Samir Shehata

Hatem Samir Shehata

Auto-generated profile, based on publicly available information

Hatem Samir Shehata

Department of Neurology, Faculty of Medicine, Cairo University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2015 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
NENaglaa A. El-Sherbiny
Naglaa A. El-Sherbiny
MMMohamed Masoud
Mohamed Masoud
NSNevin M. Shalaby
Nevin M. Shalaby
HSHatem S. Shehata
Hatem S. Shehata
There is abundance of epidemiological studies of headache in developed and western countries; however, data in developing countries and in Egypt are still lacking. This study aims to detect the prevalence of primary headache disorders in both urban and rural sectors in Fayoum governorate, Egypt. A total of 2600 subjects were included using multi-stage stratified systematic random sampling, with respondent rate of 91.3 %. A pre-designed Arabic version, interviewer-administered, pilot tested structured questionnaire was developed according to The International Classification of Headache Disorders, 3rd edition (beta version), and this questionnaire was validated and the strength of agreement in headache diagnosis was good. The 1-year headache prevalence was 51.4 %, which was more prevalent in urban dwellers. The most common primary headache type was episodic tension type headache (prevalence; 24.5 %), followed by episodic migraine (prevalence; 17.3 %), both types peaked in midlife. Headache disorders were more common in females with exception of cluster headache that showed the expected male dominance. The risk of chronic headache increased more than one fold and half when the participants were females, married, and in those with high education. More than 60 % of our participants did not seek medical advice for their headaches problem; this percentage was higher in rural areas. Primary headache disorders are common in Egypt; prevalence rate was comparable with western countries with exception of episodic tension headache. Still headache is under-estimated and under-recognized in Egypt and this problem should be targeted by health care providers.

22 November 2008 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
SHSherif M. Hamdy
Sherif M. Hamdy
HSHatem Samir
Hatem Samir
MEM. El-Sayed
M. El-Sayed
NANermin Adel
Nermin Adel
RHRasha Hasan
Rasha Hasan
The Journal of Headache and Pain is a peer-reviewed open access journal published under the brand SpringerOpen. It is specifically dedicated to researchers involved in all aspects of headache and related pain, including theory, methodology, clinical practice and care. The journal's scope is broad, reflecting the wide application of scientific advances to every branch of headache and related pain management. Within a multidisciplinary perspective, the Journal covers headache and related pain syndromes in the following fields: genetics, neurology, internal medicine, clinical pharmacology, child neuropediatrics, anesthesiology, rheumatology, otology, dentistry, neurotraumatology, neurosurgery, psychiatry, pain management, and addiction. The Journal of Headache and Pain publishes original papers, reviews, rapid communications, brief reports, and letters pertinent to the various aspects of headache and related pain. Researchers in all basic and clinical fields of headache and related pain, from molecular biology to genetics, from epidemiology to classification, from quality of life assessment to clinical trials, are becoming increasingly aware of the importance of this medical specialty. Official Journal of the European Headache Federation Official Journal of Lifting The Burden - The Global Campaign against Headache For authors and readers: All articles are published under the Creative Commons Attribution licence. You can read, redistribute and reuse the articles for free, as long as you cite the authors of the original work properly. The journal went open access in 2011, which means that all articles published since then are freely available online.

1 March 2020 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
AEAlaa Elmazny
Alaa Elmazny
SHSherif M Hamdy
Sherif M Hamdy
MAMaged Abdel-Naseer
Maged Abdel-Naseer
NSNevin M Shalaby
Nevin M Shalaby
HSHatem S Shehata
Hatem S Shehata
AHAmr Hassan
Amr Hassan
Background: Studies have shown that interferon-beta (IFN-β) treatment is associated with headaches in patients with multiple sclerosis (MS). Headaches can affect quality of life and overall function of patients with MS. We examined the frequency, relationships, patterns, and characteristics of headaches in response to IFN-β in patients with relapsing-remitting multiple sclerosis (RRMS). Patients and Methods: This study was a prospective, longitudinal analysis with 1-year follow-up. The study comprised 796 patients with RRMS treated with IFN-β (mean age 30.84± 8.98 years) at 5 tertiary referral center outpatient clinics in Egypt between January 2015 and December 2017. Headaches were diagnosed according to the International Classification of Headache Disorders ICHD-3 (beta version), and data were collected through an interviewer-administered Arabic-language-validated questionnaire with an addendum specifically designed to investigate the temporal relationship between commencement of interferon treatment, and headache onset and characteristics. Results: Two hundred seventy-six patients had pre-existing headaches, and 356 experienced de novo headaches. Of 122 patients who experienced headaches before IFN-β treatment, 55 reported headaches that worsened following onset of IFN-β treatment. In patients with post-IFN-β headaches, 329 had headaches that persisted for > 3 months, 51 had chronic headaches, and 278 had episodic headaches, and 216 of these patients required preventive therapies. Univariate analysis showed a > 6- and an approximately 5-fold increased risk of headache among those treated with intramuscular (IM) INF-β-1a (OR 6.51; 95% CI: 3.73– 10.01; P-value < 0.0001) and 44 μg of SC INF-β-1a (OR 5.44; 95% CI: 3.15– 9.37; P-value < 0.0001), respectively, compared with that in patients who received 22 μg of SC INF-β-1a. Conclusion: Interferon-β therapy aggravated pre-existing headaches and caused primary headaches in patients with MS. Headache risk was greater following treatment with IM INF-β-1a and 44 μg SC INF-β-1a.

1 September 2019 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
NKNoha Abo Koraysha
Noha Abo Koraysha
NKNirmeen Kishk
Nirmeen Kishk
AHAmr Hassan
Amr Hassan
NGNehal Maher Samy El Gendy
Nehal Maher Samy El Gendy
HSHatem S Shehata
Hatem S Shehata
YKYasmine Shawki Kamal
Yasmine Shawki Kamal
Background and purpose: The development of new biomarkers for multiple sclerosis (MS) is of paramount importance to improve our ability to predict disease progression and disability. The aim of this study was to evaluate the potential role of the optic nerve diameter (OND) measured by ultrasonography as a biomarker of early disability in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: Forty-nine RRMS patients, 23 with a history of optic neuritis (MS-ON) and 26 without a history of optic neuritis (MS N-ON), and 50 age- and sex-matched healthy control subjects were included in the study. The OND and optic nerve sheath diameter (ONSD) were measured by transorbital sonography (TOS), and the retinal nerve fibre layer (RNFL) and ganglion cell complex (GCC) thicknesses were measured by optical coherence tomography (OCT) using the Optovue RTVue™ system (Optovue, Inc., Fremont, CA, USA). Results: There was no significant difference between the patient (whether ON or N-ON eyes) and control groups in either the OND (p=0.979) or the ONSD (p=0.911). However, patients with an expanded disability status scale (EDSS) score >2 had a significantly lower OND and RNFL thicknesses (p=0.014, p=0.010 respectively) than patients with an EDSS score ≤2. Statistical logistic regression revealed that OND was an independent predictor of EDSS>2 (p=0.044, OR =0.000, 95% CI=0.000–0.589). Conclusion: The OND, as measured by ultrasonography, could be potentially used as a biomarker for the detection of early disability in RRMS patients.

1 July 2020 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
PDF file
SHSherif M Hamdy
Sherif M Hamdy
MNMaged Abdel Naseer
Maged Abdel Naseer
HSHatem S. Shehata
Hatem S. Shehata
AHAmr Hassan
Amr Hassan
AEAlaa Elmazny
Alaa Elmazny
TBThomas Berger
Thomas Berger
The emergence of the novel coronavirus disease 2019 (COVID-19) pandemic has become a major public health challenge of global concern since December 2019, when the virus was recognized in Wuhan, the capital city of Hubei province in China and epicenter of the COVID-19 epidemic. Given the novelty of COVID-19 and the lack of specific anti-virus therapies, the current management is essentially supportive. There is an absence of consensus on guidelines or treatment strategies for complex disorders such as multiple sclerosis (MS), in which the risk of infections is higher than in the general population. This is due to the overall impairment of the immune system typical of autoimmune diseases, in addition to accumulation of disabilities, and the iatrogenic effect generated by corticosteroids and the recommended disease-modifying therapies (DMTs). DMTs have different modes of action, but all modulate and interfere with the patient’s immune response, thereby raising concerns about adverse effects, such as an increased susceptibility to infections. In this review, we analyze the evidence for use of DMTs during the current critical period and ratify an algorithmic approach for management to optimize care between keeping DMTs, with their infection hazards, or coming off them, with the risk of disease activation. We also provide an algorithmic approach to the management of breakthrough activity during the COVID-19 pandemic.

1 March 2011 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
HSHatem Samir
Hatem Samir
HGHadeer Abdel Ghaffar
Hadeer Abdel Ghaffar
MNMohamed Nasr
Mohamed Nasr